This paper reports the results of 24 cases of bone defect resulting from bone tumor or tumor condition excision, and of posterior spinal fusion, treated by human bone matrix gelatin. The success rate of bone defect re...This paper reports the results of 24 cases of bone defect resulting from bone tumor or tumor condition excision, and of posterior spinal fusion, treated by human bone matrix gelatin. The success rate of bone defect repair and spinal fusion is 91. 67 %. The results suggest that human bone matrix gelatin has. excellent osteoinductive effect and is ideal substitute for bone autografts.展开更多
承钢公司生产的公称直径为32 mm PSB930预应力混凝土用螺纹钢筋在疲劳测试过程中未达到5×106次应力循环的要求,对试样断口的形貌、化学成分及金相组织进行了分析,发现疲劳试验过程中钢筋过早断裂是由试样表面缺陷引起的。同时,对...承钢公司生产的公称直径为32 mm PSB930预应力混凝土用螺纹钢筋在疲劳测试过程中未达到5×106次应力循环的要求,对试样断口的形貌、化学成分及金相组织进行了分析,发现疲劳试验过程中钢筋过早断裂是由试样表面缺陷引起的。同时,对表面光滑的试样按相同方法做疲劳试验,均达到标准要求。据此,认为该批钢筋满足疲劳标准要求,对试样加工进行了规范。展开更多
Objective To investigate the long term efficacy and side effects of a donor-derived CD19 chimeric antigen receptor (CAR) T-cell (HI19α-4-1BB-ζCAR-T) therapy in the treatment of patients with relapsed B-cell acute ly...Objective To investigate the long term efficacy and side effects of a donor-derived CD19 chimeric antigen receptor (CAR) T-cell (HI19α-4-1BB-ζCAR-T) therapy in the treatment of patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)展开更多
文摘This paper reports the results of 24 cases of bone defect resulting from bone tumor or tumor condition excision, and of posterior spinal fusion, treated by human bone matrix gelatin. The success rate of bone defect repair and spinal fusion is 91. 67 %. The results suggest that human bone matrix gelatin has. excellent osteoinductive effect and is ideal substitute for bone autografts.
文摘承钢公司生产的公称直径为32 mm PSB930预应力混凝土用螺纹钢筋在疲劳测试过程中未达到5×106次应力循环的要求,对试样断口的形貌、化学成分及金相组织进行了分析,发现疲劳试验过程中钢筋过早断裂是由试样表面缺陷引起的。同时,对表面光滑的试样按相同方法做疲劳试验,均达到标准要求。据此,认为该批钢筋满足疲劳标准要求,对试样加工进行了规范。
文摘Objective To investigate the long term efficacy and side effects of a donor-derived CD19 chimeric antigen receptor (CAR) T-cell (HI19α-4-1BB-ζCAR-T) therapy in the treatment of patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
